Detalhe da pesquisa
1.
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers.
Hepatology
; 77(6): 1943-1957, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052732
2.
Systems neuroimmunology: a review of multiomics methodologies to characterize neuroimmunological interactions in spinal and cranial diseases.
Neurosurg Focus
; 52(2): E9, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35104798
3.
Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.
Brain
; 143(12): 3629-3652, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33253355
4.
Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses.
Mol Ther
; 28(12): 2540-2552, 2020 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877695
5.
Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.
Neurosurg Focus
; 50(2): E10, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33524942
6.
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Mol Ther
; 27(6): 1139-1152, 2019 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053413
7.
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
Gut
; 67(3): 562-573, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27902444
8.
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Mol Ther
; 25(4): 962-975, 2017 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28237836
9.
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Mol Ther
; 24(1): 166-74, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26310630
10.
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.
Mol Ther
; 23(5): 845-856, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25544599
11.
BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Mol Ther
; 23(5): 931-942, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25619724
12.
Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.
J Gen Virol
; 96(Pt 7): 1533-50, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25711964
13.
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.
Mol Ther
; 22(10): 1851-63, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24957982
14.
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.
Mol Ther
; 22(11): 1936-48, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25059678
15.
The Immune System in Oncolytic Immunovirotherapy: Gospel, Schism and Heresy.
Mol Ther
; 26(4): 942-946, 2018 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573976
16.
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Mol Ther
; 21(2): 348-57, 2013 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23011032
17.
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.
Mol Ther
; 21(8): 1507-16, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23752316
18.
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.
Int J Cancer
; 132(10): 2327-38, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23114986
19.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Mol Ther
; 20(10): 1998-2003, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22871663
20.
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.
Pharmaceuticals (Basel)
; 16(6)2023 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37375742